Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20527380 | 0.87 | CA1 (0.50) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL13708463 | 0.86 | CA1 (0.54) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL5722002 | 0.85 | MGAM (0.46) | CA1CA2KMOGAAMGAM | |
| SCHEMBL13708506 | 0.85 | CA1 (0.54) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL5722157 | 0.78 | CA1 (0.62) | CA1CA2GAAALDH1A1 | |
| SCHEMBL13708465 | 0.74 | CA1 (0.53) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL5722036 | 0.73 | MGAM (0.44) | CA1CA2KMOGAAMGAM | |
| SCHEMBL1078732 | 0.71 | CA1 (0.74) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL3457639 | 0.71 | CA1 (0.59) | CA1CA2ALDH1A1NOTUM | |
| SCHEMBL5722034 | 0.70 | MGAM (0.40) | CA1CA2KMOGAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | CXCR3, CXCR1, CCR7 | CA1 2015/4885CA2 976/4885KMO 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.